NEJM:与弥散性结核相关的HLH-病例报道

2020-04-30 MedSci原创 MedSci原创

用骨髓穿刺液和痰液的DNA探针检查确定为结核分枝杆菌,并诊断为与弥散性结核相关的噬血细胞淋巴组织细胞增生症(HLH)。

患者为一名63岁的患有慢性阻塞性肺疾病(COPD)的男子,因发热、呼吸急促和神志不清到急诊就诊。他有6个月的疲劳、厌食和体重减轻6.8公斤的病史,并接受了认为是导致COPD恶化和肺炎症状的治疗。他没有咳嗽、咯血或近期旅行的报道。

患者的温度为39.3°C,呼吸频率为每分钟32次,而他在吸氧6L时的血氧饱和度为91%。实验室检查发现血小板计数为99000/立方毫米(参考范围160000至370000)和铁蛋白水平为17189ng/ml(参考范围22至275)。胸部计算机断层扫描发现两肺均出现肺部混浊,无结节或空化现象。痰的革兰氏染色阴性,痰与血液细菌培养也为阴性,干扰素γ释放测定结果不确定。

考虑到进行性血小板减少,铁蛋白水平升高和难治性败血症,需进行骨髓活检。活检显示有吞噬细胞作用(图A; Wright-Giemsa染色),以及非干酪性肉芽肿,带有耐酸杆菌(图B,箭头; Ziehl-Neelsen染色)。用骨髓穿刺液和痰液的DNA探针检查确定为结核分枝杆菌,并诊断为与弥散性结核相关的噬血细胞淋巴组织细胞增生症(HLH)。

患者入住重症监护室,开始抗结核治疗,但在就诊后55天死亡。

原始出处:

Michael Kessler,et al.HLH Associated with Disseminated Tuberculosis.N Engl J Med 2020;https://www.nejm.org/doi/full/10.1056/NEJMicm1910558

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1975625, encodeId=82a319e562585, content=<a href='/topic/show?id=04ac8964c1' target=_blank style='color:#2F92EE;'>#HLH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8964, encryptionId=04ac8964c1, topicName=HLH)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jan 14 10:59:03 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254362, encodeId=aff61254362e9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 01 22:59:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035253, encodeId=254d103525384, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 30 10:59:03 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2021-01-14 循证小兵
  2. [GetPortalCommentsPageByObjectIdResponse(id=1975625, encodeId=82a319e562585, content=<a href='/topic/show?id=04ac8964c1' target=_blank style='color:#2F92EE;'>#HLH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8964, encryptionId=04ac8964c1, topicName=HLH)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jan 14 10:59:03 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254362, encodeId=aff61254362e9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 01 22:59:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035253, encodeId=254d103525384, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 30 10:59:03 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1975625, encodeId=82a319e562585, content=<a href='/topic/show?id=04ac8964c1' target=_blank style='color:#2F92EE;'>#HLH#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8964, encryptionId=04ac8964c1, topicName=HLH)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jan 14 10:59:03 CST 2021, time=2021-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254362, encodeId=aff61254362e9, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Fri May 01 22:59:03 CST 2020, time=2020-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035253, encodeId=254d103525384, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Apr 30 10:59:03 CST 2020, time=2020-04-30, status=1, ipAttribution=)]
    2020-04-30 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

Blood:原发性嗜血性淋巴细胞增生症的无症状患儿的治疗瓶颈

原发性嗜血性淋巴细胞增生症(HLH)的致病基因致病性等位基因突变的无症状携带者易患致命性HLH,需采用造血干细胞移植(HSCT)进行治疗。目前,尚无针对无症状患者的管理指南。Giovanna Lucchini等人对双指数病例(ICs)的预后进行分析,发现随后确诊的无症状家庭成员(ACs)也携带相同的遗传缺陷。研究人员从全球的22个HSCT中心收集相关数据,共筛选到32对(64位)患者可用于评估。I

Gastroenterology:英夫利昔单抗暴露与IBD小儿患者发生恶性肿瘤或HLH的风险增加无关!

来自于大型临床试验和SEER数据库的数据得到的对年龄、性别和种族进行调整后的SIRs,研究人员发现英夫利昔单抗暴露与IBD小儿患者发生恶性肿瘤或HLH的风险增加无关。巯基嘌呤暴露是IBD小儿患者发生恶性肿瘤或HLH的一个重要前提事件。